Company Overview and News

to your dashboard

Headline News

Watch Out Gilead, Juno's Strategy Might Just Pay Off

2017-11-16 seekingalpha
Gilead acquired Kite in a blockbuster $11.9 B deal largely for its recently approved CD19 CAR-T product platform. (73-0)

Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?

2017-11-16 seekingalpha
The approval of Yescarta proved that CAR-T (based on CD4 T cells) works. Atara uses a similar mechanism of action and targets the CAR-T (that leverages on CD8). (27-0)

How To Make Money With Gilead?

2017-11-16 seekingalpha
Growth of the Hepatitis franchises seem to be at the end of its robust cycle, but tapping into the vast China market may spark further growth. (51-0)

Trade of the Day: Gilead Sciences, Inc. (GILD) | InvestorPlace

2017-11-15 investorplace
To receive further updates on this Gilead Sciences, Inc. (NASDAQ:GILD) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today.  (20-0)

7 Life Science Stocks to Buy Today | InvestorPlace

2017-11-14 investorplace
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like? (236-1)

BioLife Solutions: Third-Quarter Results Point To Continued Upside

2017-11-14 seekingalpha
Encouraging guidance bodes well and I wouldn't be surprised for 2018 revenue projections to be raised again in the future. (32-0)

Why Argus Is Taking a Step Back on Gilead Sciences

2017-11-13 247wallst
Gilead Sciences Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have hoped that the shares will pull out of their holding pattern with some M&A, but this boost only proved temporary. As a result more analysts are taking a more sideline approach to this stock. (20-0)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-8)

Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-VIgD

2017-11-12 seekingalpha
Kite Pharma licensed TIP-vIgD from Alpine Immune Science for CAR-TCR innovation. Gilead recently acquired Kite for the powerful CAR-TCR platform. (20-0)

BioLife Solutions' (BLFS) CEO Mike Rice on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day, ladies and gentlemen, and welcome to the Third Quarter 2017 BioLife Solutions Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (40-0)

Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day everyone and welcome to the CytoSorbents Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will being the call – we will open the call for your questions. Please be advised that the call will be recorded as the Company's request. (13-1)

Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?

2017-11-07 seekingalpha
Portola Pharma is a $3.5b market cap biopharmaceutical company with annualized revenue of ~$100m and a cash burn rate of ~$200m. (43-3)

Your Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA Approvals

2017-11-07 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (414-5)

CRYOPORT's (CYRX) CEO Jerry Shelton on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good afternoon ladies and gentlemen. Welcome to the Cryoport Third Quarter Earnings Conference Call. Today's conference is being recorded and will be available on the Company's website. (40-0)

Incyte Q3 Results Should Be An Upward Inflection Point

2017-11-02 seekingalpha
Incyte (INCY) was hyped as a likely acquisition target of Gilead (GILD) through most of 2017. But on August 28, 2017, Gilead announced it would acquire Kite Pharma (KITE), a developer of CART cancer therapies, for $11.9 billion. (34-2)

CUSIP: 49803L109